| Ident. | Authors (with country if any) | Title |
|---|
| 000409 (2019) |
Manuel Camean-Castillo [Espagne] ; Vicente Gimeno-Ballester [Espagne] ; Esmeralda Rios-Sanchez [Espagne] ; Silvia Fenix-Caballero [Espagne] ; Miguel Vázquez-Real [Espagne] ; Emilio Alegre-Del Rey [Espagne] | Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients. |
| 000500 (2019) |
Noemi Muszbek [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Marie Fournier [France] ; Chieh-I Chen [États-Unis] ; Andreas Kuznik [États-Unis] ; Zsofia Kiss [Royaume-Uni] ; Peter Gal [Hongrie] ; Kaleb Michaud [États-Unis] | Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. |
| 000528 (2019) |
Yi-Ming Chen [Taïwan] ; Wen-Nan Huang [Taïwan] ; Tsai-Ling Liao [Taïwan] ; Jun-Pen Chen [Taïwan] ; Sheng-Shun Yang [Taïwan] ; Hsin-Hua Chen [Taïwan] ; Tsu-Yi Hsieh [Taïwan] ; Wei-Ting Hung [Taïwan] ; Yi-Hsing Chen [Taïwan] ; Der-Yuan Chen [Taïwan] | Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy. |
| 000865 (2018) |
Alison O'Mahony [États-Unis] ; Markus R. John [Suisse] ; Hannah Cho [États-Unis] ; Misato Hashizume [Suisse] ; Ernest H. Choy [Royaume-Uni] | Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. |
| 000984 (2017) |
Benjamin Chastek [États-Unis] ; Chieh-I Chen [États-Unis] ; Clare Proudfoot [Royaume-Uni] ; Shraddha Shinde [États-Unis] ; Andreas Kuznik [États-Unis] ; Wenhui Wei [États-Unis] | Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. |
| 000A59 (2017) |
Jeffrey R. Curtis [États-Unis] ; Lang Chen [États-Unis] ; Phillip Higginbotham [États-Unis] ; W Benjamin Nowell [États-Unis] ; Ronit Gal-Levy [Israël] ; James Willig [États-Unis] ; Monika Safford [États-Unis] ; Joseph Coe [États-Unis] ; Kaitlin O'Hara [États-Unis] ; Roee Sa'Adon [Israël] | Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising. |
| 000A71 (2017) |
José Ram N Maneiro [Espagne] ; Alejandro Souto [Espagne] ; Juan J. Gomez-Reino [Espagne] | Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. |
| 000A72 (2017) |
Simon Tarp [Danemark] ; Daniel Eric Furst [États-Unis] ; Maarten Boers ; George Luta [États-Unis] ; Henning Bliddal [Danemark] ; Ulrik Tarp ; Karsten Heller Asmussen [Danemark] ; Birgitte Brock ; Anna Dossing [Danemark] ; Tanja Schj Dt J Rgensen [Danemark] ; Steffen Thirstrup [Danemark] ; Robin Christensen [Danemark] | Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. |
| 000B66 (2017) |
Naoki Iwamoto [Japon] ; Sosuke Tsuji [Japon] ; Ayuko Takatani [Japon] ; Toshimasa Shimizu [Japon] ; Shoichi Fukui [Japon] ; Masataka Umeda [Japon] ; Ayako Nishino [Japon] ; Yoshiro Horai [Japon] ; Tomohiro Koga [Japon] ; Shin-Ya Kawashiri [Japon] ; Toshiyuki Aramaki [Japon] ; Kunihiro Ichinose [Japon] ; Yasuko Hirai [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Kaoru Terada [Japon] ; Tomoki Origuchi [Japon] ; Katsumi Eguchi [Japon] ; Yukitaka Ueki [Japon] ; Atsushi Kawakami [Japon] | Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. |
| 000B93 (2017) |
Jeroen P. Jansen [États-Unis] ; Devin Incerti [États-Unis] ; Alex Mutebi [États-Unis] ; Desi Peneva [États-Unis] ; Joanna P. Macewan [États-Unis] ; Bradley Stolshek [États-Unis] ; Primal Kaur [États-Unis] ; Mahdi Gharaibeh [États-Unis] ; Vibeke Strand [États-Unis] | Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. |
| 000C11 (2017) |
Jasvinder A. Singh ; Alomgir Hossain ; Elizabeth Tanjong Ghogomu ; Amy S. Mudano [États-Unis] ; Lara J. Maxwell ; Rachelle Buchbinder ; Maria Angeles Lopez-Olivo ; Maria E. Suarez-Almazor ; Peter Tugwell ; George A. Wells | Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. |
| 000C12 (2017) |
Jasvinder A. Singh ; Alomgir Hossain ; Amy S. Mudano [États-Unis] ; Elizabeth Tanjong Ghogomu ; Maria E. Suarez-Almazor ; Rachelle Buchbinder ; Lara J. Maxwell ; Peter Tugwell ; George A. Wells | Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. |
| 000C67 (2016) |
Yutaka Kawahito | [Guidelines for the management of rheumatoid arthritis]. |
| 000C87 (2016) |
Maria-Cecilia Vieira [États-Unis] ; Samuel H. Zwillich [États-Unis] ; Jeroen P. Jansen [États-Unis] ; Brielan Smiechowski [États-Unis] ; Dean Spurden [Royaume-Uni] ; Gene V. Wallenstein [États-Unis] | Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. |
| 000D68 (2016) |
Jeffrey R. Curtis [États-Unis] ; Fenglong Xie [États-Unis] ; Huifeng Yun [États-Unis] ; Sasha Bernatsky [Canada] ; Kevin L. Winthrop [États-Unis] | Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. |
| 000E99 (2016) |
Young Ho Lee [Corée du Sud] ; Sang-Cheol Bae [Corée du Sud] | Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. |
| 000F13 (2016) |
Fenglong Xie ; Huifeng Yun ; Sasha Bernatsky [Canada] ; Jeffrey R. Curtis [États-Unis] | Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. |
| 000F17 (2016) |
Jasvinder A. Singh ; Alomgir Hossain ; Elizabeth Tanjong Ghogomu ; Ahmed Kotb ; Robin Christensen ; Amy S. Mudano ; Lara J. Maxwell ; Nipam P. Shah ; Peter Tugwell ; George A. Wells | Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. |
| 000F21 (2016) |
Jasvinder A. Singh ; Alomgir Hossain ; Elizabeth Tanjong Ghogomu ; Amy S. Mudano ; Peter Tugwell ; George A. Wells | Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). |
| 000F39 (2016) |
Allison B. Webber [États-Unis] ; Flavio Vincenti | An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed. |
| 000F40 (2016) |
Lindsay Claxton [Royaume-Uni] ; Michelle Jenks [Royaume-Uni] ; Matthew Taylor [Royaume-Uni] ; Gene Wallenstein [États-Unis] ; Alan M. Mendelsohn [États-Unis] ; Jeffrey A. Bourret [États-Unis] ; Amitabh Singh [États-Unis] ; Dermot Moynagh [États-Unis] ; Robert A. Gerber [États-Unis] | An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. |
